Relative Bioavailability

Relative bioavailability compares the systemic exposure of a test product with that of a non-intravenous reference, such as another formulation, another route, or the same drug given with or without food. Rather than measuring the absolute fraction reaching the blood, it expresses one product's availability as a proportion of another's, making it the natural metric for comparing dosage forms and conditions of administration.

Definition

Relative bioavailability is the dose-corrected ratio of systemic exposure (area under the plasma concentration-time curve) of a test product to that of a chosen non-intravenous reference product, quantifying how the two compare in extent of absorption.

Scope

The entry covers the definition of relative bioavailability, its dose-normalised area-under-the-curve ratio, the reference products it is measured against, and its role as the quantitative basis for comparing formulations. It is presented as a comparative measurement concept in biopharmaceutics, not as substitution or dosing advice.

Core questions

• How does the exposure from one formulation compare with that from another?
• Why is a non-intravenous product, rather than an intravenous dose, the reference here?
• How is relative bioavailability computed from AUC and dose?
• How does relative bioavailability relate to bioequivalence assessment?

Key concepts

• Comparative exposure ratio
• Test versus reference product
• Dose-normalised AUC ratio
• Formulation comparison
• Foundation for bioequivalence testing

Mechanisms

Relative bioavailability is obtained by comparing the dose-normalised area under the concentration-time curve of a test product with that of a reference product administered by the same or a different extravascular route. Because both products are subject to absorption and presystemic losses, the ratio cancels intravenous referencing and instead isolates the difference attributable to formulation, route, or conditions such as fed versus fasted dosing. A relative bioavailability near one indicates comparable extent of absorption, whereas departures signal that formulation or administration conditions have altered how much drug reaches the circulation. This comparative ratio is the quantity that bioequivalence studies subsequently subject to formal statistical equivalence testing.

Clinical relevance

Relative bioavailability explains why a change in formulation, salt form, or administration condition can raise or lower systemic exposure even when the labelled dose is unchanged. It is a reference concept for interpreting comparative exposure between products; it describes how formulations differ and is not a basis for individual substitution or dosing decisions.

Evidence & guidelines

Relative bioavailability is measured in comparative pharmacokinetic studies, typically crossover designs, and it provides the exposure ratio that bioequivalence assessment evaluates against equivalence limits. Frameworks linking physicochemical properties to absorption, such as the Biopharmaceutics Classification System of Amidon and colleagues, help anticipate when formulation changes will affect relative bioavailability, and Hellriegel and colleagues showed that poorly absorbed drugs exhibit greater variability in such comparisons.

History

As pharmacokinetic measurement matured, comparing formulations by their exposure ratios became a routine tool of drug development, distinct from the intravenous-referenced absolute measure. Relative bioavailability was incorporated into standard pharmacokinetic teaching and became the conceptual precursor to formal bioequivalence testing as regulatory comparison of products grew in importance.

Key figures

• Malcolm Rowland
• Thomas Tozer
• Gordon Amidon

Seminal works

• hellriegel-1996
• amidon-1995

Frequently asked questions

How does relative bioavailability differ from absolute bioavailability?

Absolute bioavailability compares an extravascular dose to an intravenous reference to give the true fraction reaching the blood, while relative bioavailability compares one extravascular product to another non-intravenous reference to give a comparative ratio.

When is relative bioavailability the appropriate measure?

It is used when the goal is to compare formulations, routes, or administration conditions with one another rather than to quantify the absolute fraction of dose that reaches the circulation.